<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-498-06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ATORMIN 100MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ATENOLOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        16.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OMAN PHARMACEUTICAL PRODUCTS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C07AB03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>COMPOSITION:</p><p>Atormin 100 Each tablet contains Atenolol BP 100 mg.</p><p>&nbsp;</p><p>PROPERTIES :</p><p>Atormin is a beta-1-adrenoceptor blocking agent without intrinsic sympathomimetic or membrane stablising activities i.e cardioselective.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>CONTRA-INDICATIONS:</strong></p><p>Atormin is contraindicated in case of hypersensitivity, hypotension, metabolic acidosis, severe peripheral arterial circulatory disturbance, untreated pheochromocytoma.</p><p>Atormin is contraindicated in sick sinus syndrome,second or third degree atrioventricular block,cardiogenic shock and overt cardiac failure.</p><p>&nbsp;</p><p><strong>WARNINGS: </strong></p><p>Particular caution should be exercised with patients suffering from the following:</p><p>Bradycardia of less than 50 pulse beats a minute</p><p>Peripheral vascular disease</p><p>Raynaud&rsquo;s phenomenon</p><p>The normal dose should be reduced in elderly patients, or in patients suffering from renal dysfunction.</p><p>As with other adrenoceptor blocking agents, discontinuation of the drug should be gradual in patients with ischaemic heart disease. In patients who have congestive heart failure controlled by digitalis and or diuretics, atenolol should be administered cautiously. Both, digitalis and atenolol slow AV conduction.</p><p>&nbsp;</p><p>INTERACTIONS:</p><p>Anaesthetics: Care should be taken when anaesthetic agents are used with atenolol. The patient should be warned to inform the anaesthetist.</p><p>It can be dangerous to administer Atormin concomitantly with the following agents: hypoglycaemic agents, phenothiazines and class 1 antiarrhythmic agents such as disopyramide. Such interactions can have life-threatening consequences.</p><p>Combined use of atenolol and calcium channel blockers with negative inotropic effects such as verapamil and diltiazem can lead to an exaggeration of these effects, particularly in patients with impaired ventricular function and/or SA or AV conduction abnormalities. This may result in severe hypotension, bradycardia and cardiac failure. Neither medicine should be administered intravenously within 48 hours of discontinuing the other.</p><p>Concomitant use of sympathomimetic agents e.g. adrenaline, may counteract the effect of beta-blockers.</p><p>Concomitant use of prostaglandin synthetase inhibiting drugs (e.g. ibuprofen, indomethacin), may decrease the hypotensive effects of beta-blockers.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>INDICATIONS:</strong></p><p>Atormin is indicated for</p><p>&bull; Mild to moderate hypertension.</p><p>&bull; Angina pectoris.</p><p>&bull; Cardiac arrhythmias.</p><p>&bull; Myocardial infarction; Early and late intervention.</p><p>&nbsp;</p><p><strong>DOSAGE AND DIRECTIONS FOR USE:</strong></p><p>Hypertension:</p><p>50-100 mg daily, given orally as a single dose.</p><p>Angina Pectoris:</p><p>The usual dose is 100 mg daily given as a single or divided dose.</p><p>Cardiac arrhythmias:</p><p>Oral maintenance dosage is 50-100mg. daily given as a single dose.</p><p>Myocardial infarction:</p><p>Early intervention after acute myocardial infarction:</p><p>For patients suitable for intravenous beta blockade treatment, Atenolol 5-10 mg (10 to 20 ml; 1 mg / minute) should be given within 12 hours of onset of chest pain. If no untoward effects occur, &lsquo;Atormin&rsquo; 50 mg given orally about 15 minutes later followed by Atormin 50 mg orally at 12 hours interval and further followed by Atormin 100 mg orally once daily. &lsquo;Atormin&rsquo; should be discontinued, if bradycardia and / or hypotension or any other untoward effects occur.</p><p>Late intervention after myocardial infarction: For patients who present some days after suffering from an acute myocardial infarction, an oral dose of&nbsp; Atormin 1 tablet (100 mg) daily is recommended for long-term prophylaxis.</p><p>Children: There is no experience in children.</p><p>&nbsp;</p><p><strong>OVERDOSAGE:</strong></p><p>Excessive bradycardia can be countered with atropine 1-2 mg intravenously. If necessary, this may be followed by a bolus dose of glucagons 10 mg intravenously. If required, this may be repeated or followed by an intravenous infusion of glucagons 1-10 mg/hour depending on response. If no response to glucagons occurs or if glucagons is unavailable, a beta-adrenoceptor stimulant such as dobutamine 2.5 to 10&micro;g/kg/minute by intravenous infusion or isoprenaline 10 to 25&micro;g given as an infusion at a rate not exceeding 5&micro;g/ minute may be given. It is likely that these doses would be inadequate to reverse the cardiac effects of beta-blockade if a large overdose has been taken. The dose of dobutamine or Isoprenaline should therefore be increased if necessary to achieve the required response according to the clinical condition of the patient.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>SIDE-EFFECTS AND SPECIAL PRECAUTIONS:</strong></p><p style="text-align:justify"><strong>SIDE-EFFECTS</strong></p><p style="text-align:justify">Side-effects include fatigue and coldness of the extremities. Cardiovascular effects include bradycardia and hypotension.</p><p style="text-align:justify">In some patients bronchospasm and peripheral vasoconstriction may occur. Central nervous system effects include depression, confusion and sleep disturbances.</p><p style="text-align:justify">Gastro-intestinal side-effects include nausea, vomiting, diarrhoea, constipation and abdominal cramping.</p><p style="text-align:justify">Skin rash, pruritus .</p><p>&nbsp;</p><p style="text-align:justify"><strong>PRECAUTIONS:</strong></p><p style="text-align:justify">Pregnancy: Atenolol crosses the placental barrier and appears in cord blood. Administration to pregnant women has been associated with intra-uterine growth retardation. Administration of atenolol to pregnant mothers shortly before giving birth, or during labour may result in the newborn infants being born hypotonic, collapsed and hypoglycaemic.</p><p style="text-align:justify">Special care should be taken with patients whose cardiac reserve is poor. Patients with bronchospastic disease should in general, not receive beta-blockers. Because of its beta1- selectivity, atenolol may be used with caution in patients with bronchospastic disease.</p><p style="text-align:justify">Atenolol may aggravate peripheral arterial circulatory disorders.</p><p style="text-align:justify">Atenolol modifies the tachycardia of hypoglycaemia.&nbsp;</p><p style="text-align:justify">There is significant accumulation in breast milk. Breastfeeding patients must not take atenolol.</p><p style="text-align:justify">Beta-blockers may exacerbate the rebound hypertension which can follow the withdrawl of clonidine. If the two drugs are co-administered, the beta-blocker should be withdrawn several days before discontinuing clonidine. If replacing Clonidine by beta-blocker therapy, the introduction should be delayed for several days after clonidine administration has stopped.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>STORAGE INSTRUCTIONS: Store between 15&deg;C to 25&deg;C. Protect from Light and moisture.</p><p>KEEP OUT OF THE REACH OF CHILDREN.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Atormin 100 Each tablet contains Atenolol BP 100 mg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Atormin tablets 25, 50 & 100 mg, are available in Strip of 14  tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Oman Pharmaceutical Products Co., LLC</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2009.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>التركيب:</strong></p><p>كل قرص أتورمين 100 يحتوي على 100 ملجم أتينولول</p><p dir="RTL"><strong>الخواص:</strong></p><p dir="RTL">أتورمين هو دواء مستقلب لمستقبل بيتا &ndash; 1- الأدريناليني وليس له تأثير ضمني كمقلد للودي أو تأثيرات غشائية مثبتة (انتقائي للقلب).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع الاستعمال:</strong></p><p dir="RTL">الحساسية للدواء، في حالات الضغط المنخفض، الحموضة الإستقلابية، الإضطرابات الشديدة في الدورة الشريانية الطرفية، والفيوكروموسيتوما الغير قابلة للعلاج.</p><p dir="RTL">لا يعطى الأتينولول في حالة بطء القلب الجيبي، الانسداد البطيني الأذيني من الدرجة التانية أو الثالثة، الصدمة القلبية المنشأ وعند قصور القلب الواضح.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذير:</strong></p><p dir="RTL">يجب توخي الحذر الخاص عند المرضى الذين يعانون من:</p><p dir="RTL">بطء نبض القلب إلى أقل من 50 نبضة في الدقيقة.</p><p dir="RTL">أمراض الأوعية الدموية الطرفية.</p><p dir="RTL">ظاهرة راينود.</p><p dir="RTL">يجب خفض الجرعة المعتادة عند كبار السن أو عند المرضى الذين يعانون من اختلال في وظائف الكلى.</p><p dir="RTL">وكما هو الحال مع عوامل حاجبات مستقبل بيتا الأخرى فإن ايقاف المعالجة يجب أن يكون بشكل تدريجي عند المرضى المصابين بالافقار القلبي.</p><p dir="RTL">يجب أن يستعمل أتينولول بحذر عند المرضى المصابين بقصور القلب الاحتقاني والذين يعالجون بالديجيتاليس أو مدرات البول حيث أن كلا من الديجيتاليس والأتينولول يقللان من التوصيل الأذيني البطيني.</p><p dir="RTL"><strong>التفاعلات الدوائية:</strong></p><p dir="RTL">أدوية التخدير: يجب الحذر عند إستعمال أدوية التخدير، ويحذر المريض بأن عليه إخبار طبيب التخدير بأنه يتناول الأتينولول.</p><p dir="RTL">من الخطر تناول الأدوية الآتية مع الأتينولول:</p><p dir="RTL">الأدوية المخفضة لسكر الدم، الفينوثيازين، الأدوية المعالجة لعدم انتظام القلب من الدرجة الأولى مثل ديسوبيراميد. تداخلات كهذه يمكن أن تحدث خطورة على الحياة.</p><p dir="RTL">تناول الأتينولول مع حاجبات قنوات الكالسيوم ذات التأثيرات العضلية السلبية مثل الفيراباميل أو ديلتيازيم من الممكن أن يؤدي إلى تأثيرات مبالغ فيها خاصة لدى المرضى الذين يعانون من اختلال في وظائف البطين و/ أو توصيلات SA أو AV غير الطبيعية. حيث أنه من الممكن أن يؤدي إلى هبوط شديد في ضغط الدم وبطء قلبي و قصور قلبي. لذا يجب عدم تعاطي أي منهم وريديا قبل وقف الدواء الآخر على الأقل بـ48 ساعة.</p><p dir="RTL">إن الاستعمال المرافق للعناصر مقلدة الودي مثل الأدرينالين يمكن أن يعاكس تأثير حاجبات بيتا.</p><p dir="RTL">إن الاستعمال المرافق للعقاقير المثبطة لتصنيع البروستاغلاندينات (مثل الأيبوبروفين الأندوميثاسين) يمكن أن يقلل من التأثيرات الخافضة للضغط لحاجبات بيتا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>دواعي الاستعمال:</strong></p><p dir="RTL">يستعمل أتورمين من أجل:</p><p dir="RTL">&uuml;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج ضغط الدم البسيط والمتوسط.</p><p dir="RTL">&uuml;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيطرة على الذبحة الصدرية.</p><p dir="RTL">&uuml;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الانتظام القلبي.</p><p>الاحتشاء القلبي: للوقاية طويلة الأجل بعد الاستشفاء</p><p dir="RTL"><strong>الجرعة وتعليمات الاستعمال:</strong></p><p dir="RTL"><strong><u>ضغط الدم المرتفع:</u></strong></p><p dir="RTL">50-100 ملجم يومياً تعطى كجرعة واحدة عن طريق الفم.</p><p dir="RTL"><strong><u>الذبحة الصدرية:</u></strong></p><p dir="RTL">الجرعة المعتادة هي 100 ملجم يومياً تعطى كجرعة واحدة أو مقسمة.</p><p dir="RTL"><strong><u>عدم الانتظام:</u></strong></p><p dir="RTL">تعطى جرعة فمّية واحدة لإدامة التأثيرات من 50-100 ملجم.</p><p dir="RTL"><strong><u>الإحتشاء القلبي:</u></strong></p><p dir="RTL">التدخل المبكر بعد حدوث الاحتشاء القلبي الحاد:</p><p dir="RTL">المرضى الذين يتحملون العلاج بحاجبات بيتا عن طريق الري الوريدي يجب أن يعالجوا خلال 12 ساعة من بدء الشعور بألم في الرئة، يعطى أتينولول 5-10 ملجم (10 &ndash; 20 مل، 1 ملجم/ دقيقة)، ثم تعطى أتورمين 50 ملجم عن طريق الفم بعد حوالي 15&nbsp; دقيقة شريطة عدم ظهور أعراض جانبية من جرعة الري الوريدي، ثم بعد 12 ساعة يعطى المريض 100 ملجم عن طريق الفم لتصبح تعطى مرة واحدة يومياً. يجب وقف استخدام الأتورمين عند حدوث بطء في نبضات القلب وهبوط في ضغط الدم وغيرها من الآثار الجانبية.</p><p dir="RTL">العلاج المتأخر بعد حدوث الإحتشاء القلبي:</p><p dir="RTL">ينصح بإعطاء المرضى الذين يحضرون بعد بضعة أيام من الإحتشاء القلبي الحاد قرص واحد من أتورمين عن طريق الفم وذلك للوقاية طويلة الأجل.</p><p dir="RTL">&nbsp;</p><p><strong><u>الأطفال:</u></strong> لا توجد خبرة لاستعماله عند الأطفال</p><p dir="RTL"><strong>الجرعة الزائدة:</strong></p><p dir="RTL">بطء القلب الزائد يمكن أن يعكس بالأتروبين 1-2 ملجم عن طريق الوريد، وإذا كان ضرورياً يمكن الحاق هذه الجرعة بجرعة جلوكاجون 10 ملجم عن طريق الوريد، عند الضرورة أن تكرر جرعة الجلوكاجون أو يمكن أن تلحق بجلوكاجون عن طريق الري الوريدي 1-10 ملجم/ ساعه حسب استجابة المريض. إذا لم تحدث استجابة بجلوكاجون أو أن الجلوكاجون غير متوفر فيمكن إستعمال منشط لمستقبل بيتا الأدرينالي مثل دوبيوتامين 5و2 إلى 10 ميكروجرام/ كجم/ دقيقة عن طريق الري الوريدي أو استعمال إيزوبرينالين 10 إلى 25 ميكروجرام تعطى عن طريق الري الوريدي بسرعة لا تزيد عن 5 ميكروجرام/ دقيقة.</p><p dir="RTL">من الممكن أن تكون هذه الجرعات غير كافية لعكس التأثير القلبي لحاجبات مستقبل بيتا إذا كان المريض قد تناول جرعة مفرطة في الزيادة، في هذه الحالة يجب زيادة جرعة الدوبيوتامين أو الإيزو برينالين عند الضرورة للوصول إلى التأثير المطلوب إعتماداً على الحالة السريرية للمريض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الآثار الجانبية:</strong></p><p dir="RTL">تشمل الآثار الجانبية إرهاق عام وبرودة في الأطراف.</p><p dir="RTL">الآثار الجانبية القلبية تشمل: نقص في ضربات القلب، هبوط في الضغط.</p><p dir="RTL">قد يحدث عند بعض المرضى تشنج شعبي و انقباض الأوعية الطرفية.</p><p dir="RTL">الآثار الجانبية فيما يخص الجهاز العصبي المركزي تشمل: إكتئاب، تشويش، اضطراب، في النوم.</p><p dir="RTL">الآثار الجانبية فيما يخص الجهاز الهضمي تشمل: غثيان، قيء، إسهال، إمساك، اضطرابات معوية. حكة جلدية، هرش.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات الخاصة</strong>:</p><p dir="RTL">الحمل: يمر الأتينولول من خلال حبل المشيمة ويظهر في دم الحبل السري.</p><p dir="RTL">تناول الحوامل لهذا الدواء ترافق مع تأخر في نمو الرحم من الداخل. في حال تناول الحوامل له قبل أو أثناء الولادة قد يسبب للمواليد&nbsp; نقص في التوتر، نعاس، وإنهيار ونقص في مقدار السكر في الدم.</p><p dir="RTL">يجب أن يتوخى الحذر عند المرضى الذين يعانون من نفض المدخر القلبي.</p><p dir="RTL">يجب بشكل عام عدم إعطاء حاجبات مستقبل بيتا للمرضى المصابين بمرض التشنج القصبي.</p><p dir="RTL">بما أن الأتينولول عامل إنتقائي لمستقبل بيتا (1) يمكن استعماله بحذر لدى المرضى المصابين بمرض التشنج القصبي.</p><p dir="RTL">من الممكن للأتينولول أن يفاقم اضطرابات الدورة الدموية الطرفية.</p><p dir="RTL">نظراً لتراكم الأتينولول في حليب الأم يجب عدم إعطائه للأمهات المرضعات.</p><p dir="RTL">إن حاجبات بيتا يمكن أن تفاقم إعادة ارتفاع ضغط الدم التي تلي إيقاف المعالجة بالكلونيدين. إذا أعطي هذين العقارين في وقت واحد فإن حاجبات مستقبل بيتا يجب أن توقف قبل عدة أيام من إيقاف الكلونيدين.</p><p dir="RTL">في حال استبدال الكلونيدين بحاجب مستقبل بيتا فإن بدء المعالجة بحاجب مستقبل بيتا يجب أن يؤخر لعدة أيام بعد إيقاف المعالجة بالكلونيدين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تعليمات التخزين:</strong></p><p dir="RTL">يحفظ في درجة حرارة بين 15-25 م وبعيداً عن الضوء والرطوبة.</p><p dir="RTL">يحفظ بعيداً عن متناول أيدي الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كل قرص أتورمين 50 يحتوي على 50 ملجم أتينولول</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أتورمين 100&nbsp;ملجم متوفر في شريط يحتوي على 14 قرص</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة العمانية لمستحضرات الصيدلة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2009
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1. Name of the medicinal product
Atormin 100 mg Tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2. Qualitative and quantitative composition
Atenolol-100 mg
Excipient with known effect: Sunset yellow. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3. Pharmaceutical form
Film-coated tablet.
Description: Orange coloured, circular, film coated tablets having AT100 engraved on one side and break line on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4. Clinical particulars</strong></p><p><strong>4.1 Therapeutic indications</strong></p><p>Atormin is indicated in the treatment of:</p><p>&bull; Management of hypertension.</p><p>&bull; Management of angina pectoris and cardiac arrhythmias..</p><p>&bull; Management of myocardial infarction. Early intervention in the acute phase.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.2 Posology and method of administration</strong></p><p><strong><u>Posology</u></strong></p><p>The dose must always be adjusted to individual requirements of the patients, with the lowest possible starting dosage. The following are guidelines:</p><p><strong>Adults</strong></p><p><strong>Hypertension</strong></p><p>One tablet daily. Most patients respond to 100 mg daily given orally as a single dose. Some patients, however, will respond to 50 mg given as a single daily dose. The effect will be fully established after one to two weeks. A further reduction in blood pressure may be achieved by combining Atormin with other antihypertensive agents. For example co-administration of Atormin with a diuretic, as in Tenoretic, provides a highly effective and convenient antihypertensive therapy.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Angina</strong></p><p>Most patients with angina pectoris will respond to 100 mg given orally once daily or 50 mg given twice daily. It is unlikely that additional benefit will be gained by increasing the dose.</p><p><strong>Cardiac arrhythmias</strong></p><p>A suitable initial dose of Atormin is 2.5 mg (5 ml) injected intravenously over a 2.5 minute period (i.e. 1 mg/minute). (See also prescribing information for Atormin Injection.) This may be repeated at 5 minute intervals, until a response is observed up to a maximum dosage of 10 mg. If Atormin is given by infusion, 0.15 mg/kg bodyweight may be administered over a 20 minute period. If required, the injection or infusion may be repeated every 12 hours. Having controlled the arrhythmias with intravenous Atormin, a suitable oral maintenance dosage is 50&ndash;100 mg daily, given as a single dose.</p><p><strong>Myocardial infarction</strong></p><p>For patients suitable for treatment with intravenous beta-blockade and presenting within 12 hours of the onset of chest pain, Atormin 5&ndash;10 mg should be given by slow intravenous injection (1 mg/minute) followed by Atormin 50 mg orally about 15 minutes later, provided no untoward effects have occurred from the intravenous dose. This should be followed by a further 50 mg orally 12 hours after the intravenous dose, and then 12 hours later by 100 mg orally, once daily. If bradycardia and/or hypotension requiring treatment, or any other untoward effects occur, Atormin should be discontinued.</p><p><strong>Older population</strong></p><p>Dosage requirements may be reduced, especially in patients with impaired renal function.</p><p><strong>Paediatric population</strong></p><p>There is no paediatric experience with Atormin and for this reason it is not recommended for use in children.</p><p><strong>Renal failure</strong></p><p>Since Atormin is excreted via the kidneys, the dosage should be adjusted in cases of severe impairment of renal function.</p><p>No significant accumulation of Atormin occurs in patients who have a creatinine clearance greater than 35 ml/min/1.73 m<sup>2</sup>(normal range is 100&ndash;150 ml/min/1.73 m<sup>2</sup>).</p><p>For patients with a creatinine clearance of 15&ndash;35 ml/min/1.73 m<sup>2</sup>&nbsp;(equivalent to serum creatinine of 300&ndash;600 micromol/litre), the oral dose should be 50 mg daily and the intravenous dose should be 10 mg once every two days.</p><p>For patients with a creatinine clearance of less than 15 ml/min/1.73 m<sup>2</sup>&nbsp;(equivalent to serum creatinine of greater than 600 micromol/litre), the oral dose should be 25 mg daily or 50 mg on alternate days and the intravenous dose should be 10 mg once every four days.</p><p>Patients on haemodialysis should be given 50 mg orally after each dialysis; this should be done under hospital supervision as marked falls in blood pressure can occur.</p><p><strong><u>Method of administration</u></strong></p><p>For administration by the oral route.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3 Contraindications
Atormin, as with other beta-blockers, should not be used in patients with any of the following:
• hypersensitivity to the active substance, or to any of the excipients listed in section 6.1
• cardiogenic shock
• uncontrolled heart failure
• sick sinus syndrome
• second-or third-degree heart block
• untreated phaeochromocytoma
• metabolic acidosis
• bradycardia (<45 bpm)
• hypotension
• severe peripheral arterial circulatory disturbances.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.4 Special warnings and precautions for use</strong></p><p>Atormin as with other beta-blockers:</p><p>&bull; Should not be withdrawn abruptly. The dosage should be withdrawn gradually over a period of 7&ndash;14 days, to facilitate a reduction in beta-blocker dosage. Patients should be followed during withdrawal, especially those with ischaemic heart disease.</p><p>&bull; When a patient is scheduled for surgery, and a decision is made to discontinue beta-blocker therapy, this should be done at least 24 hours prior to the procedure. The risk-benefit assessment of stopping beta-blockade should be made for each patient. If treatment is continued, an anaesthetic with little negative inotropic activity should be selected to minimise the risk of myocardial depression. The patient may be protected against vagal reactions by intravenous administration of atropine.</p><p>&bull; Although contraindicated in uncontrolled heart failure (see section 4.3), may be used in patients whose signs of heart failure have been controlled. Caution must be exercised in patients whose cardiac reserve is poor.</p><p>&bull; May increase the number and duration of angina attacks in patients with Prinzmetal&#39;s angina due to unopposed alpha-receptor mediated coronary artery vasoconstriction. Atormin is a beta<sub>1</sub>-selective beta-blocker; consequently, its use may be considered although utmost caution must be exercised.</p><p>&bull; Although contraindicated in severe peripheral arterial circulatory disturbances (see section 4.3), may also aggravate less severe peripheral arterial circulatory disturbances.</p><p>&bull; Due to its negative effect on conduction time, caution must be exercised if it is given to patients with first-degree heart block.</p><p>&bull; May mask the symptoms of hypoglycaemia, in particular, tachycardia.</p><p>&bull; May mask the signs of thyrotoxicosis.</p><p>&bull; Will reduce heart rate as a result of its pharmacological action. In the rare instances when a treated patient develops symptoms which may be attributable to a slow heart rate and the pulse rate drops to less than 50&ndash;55 bpm at rest, the dose should be reduced.</p><p>&bull; May cause a more severe reaction to a variety of allergens when given to patients with a history of anaphylactic reaction to such allergens. Such patients may be unresponsive to the usual doses of adrenaline (epinephrine) used to treat the allergic reactions.</p><p>&bull; May cause a hypersensitivity reaction including angioedema and urticaria.</p><p>&bull; Should be used with caution in the elderly, starting with a lesser dose (see Section 4.2).</p><p>Since Atormin is excreted via the kidneys, dosage should be reduced in patients with a creatinine clearance of below 35 ml/min/1.73 m<sup>2</sup>.</p><p>Although cardioselective (beta<sub>1</sub>) beta-blockers may have less effect on lung function than non-selective beta-blockers, as with all beta-blockers, these should be avoided in patients with reversible obstructive airways disease, unless there are compelling clinical reasons for their use. Where such reasons exist, Atormin may be used with caution. Occasionally, some increase in airways resistance may occur in asthmatic patients however, and this may usually be reversed by commonly used dosage of bronchodilators such as salbutamol or isoprenaline. The label and patient information leaflet for this product state the following warning: &ldquo;If you have ever had asthma or wheezing, you should not take this medicine unless you have discussed these symptoms with the prescribing doctor&rdquo;.</p><p>As with other beta-blockers, in patients with a phaeochromocytoma, an alpha-blocker should be given concomitantly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.5 Interaction with other medicinal products and other forms of interaction</strong></p><p>Combined use of beta-blockers and calcium channel blockers with negative inotropic effects, e.g. verapamil and diltiazem, can lead to an exaggeration of these effects particularly in patients with impaired ventricular function and/or sinoatrial or atrioventricular conduction abnormalities. This may result in severe hypotension, bradycardia and cardiac failure. Neither the beta-blocker nor the calcium channel blocker should be administered intravenously within 48 hours of discontinuing the other.</p><p>Concomitant therapy with dihydropyridines, e.g. nifedipine, may increase the risk of hypotension, and cardiac failure may occur in patients with latent cardiac insufficiency.</p><p>Digitalis glycosides, in association with beta-blockers, may increase atrioventricular conduction time.</p><p>Beta-blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are co-administered, the beta-blocker should be withdrawn several days before discontinuing clonidine. If replacing clonidine by beta-blocker therapy, the introduction of beta-blockers should be delayed for several days after clonidine administration has stopped. (See also prescribing information for clonidine.)</p><p>Class I anti-arrhythmic drugs (e.g. disopyramide) and amiodarone may have a potentiating effect on atrial-conduction time and induce negative inotropic effect.</p><p>Concomitant use of sympathomimetic agents, e.g. adrenaline (epinephrine), may counteract the effect of beta-blockers.</p><p>Concomitant use with insulin and oral antidiabetic drugs may lead to the intensification of the blood sugar lowering effects of these drugs. Symptoms of hypoglycaemia, particularly tachycardia, may be masked (see section 4.4).</p><p>Concomitant use of prostaglandin synthetase-inhibiting drugs, e.g. ibuprofen and indometacin, may decrease the hypotensive effects of beta-blockers.</p><p>Caution must be exercised when using anaesthetic agents with Atormin. The anaesthetist should be informed and the choice of anaesthetic should be an agent with as little negative inotropic activity as possible. Use of beta-blockers with anaesthetic drugs may result in attenuation of the reflex tachycardia and increase the risk of hypotension. Anaesthetic agents causing myocardial depression are best avoided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.6 Fertility, pregnancy and lactation</strong></p><p>Caution should be exercised when Atormin is administered during pregnancy or to a woman who is breast-feeding.</p><p><strong><u>Pregnancy</u></strong></p><p>Atormin crosses the placental barrier and appears in the cord blood. No studies have been performed on the use of Atormin in the first trimester and the possibility of foetal injury cannot be excluded. Atormin has been used under close supervision for the treatment of hypertension in the third trimester. Administration of Atormin to pregnant women in the management of mild to moderate hypertension has been associated with intra-uterine growth retardation.</p><p>The use of Atormin in women who are, or may become, pregnant requires that the anticipated benefit be weighed against the possible risks, particularly in the first and second trimesters, since beta-blockers, in general, have been associated with a decrease in placental perfusion which may result in intra-uterine deaths, immature and premature deliveries.</p><p><strong><u>Breast-feeding</u></strong></p><p>There is significant accumulation of Atormin in breast milk.</p><p>Neonates born to mothers who are receiving Atormin at parturition or breast-feeding may be at risk of hypoglycaemia and bradycardia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.7 Effects on ability to drive and use machines</strong></p><p>Atormin has no or negligible influence on the ability to drive and use machines. However, it should be taken into account that occasionally dizziness or fatigue may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.8 Undesirable effects</strong></p><p>Atormin is well tolerated. In clinical studies, the undesired events reported are usually attributable to the pharmacological actions of atenolol.</p><p>The following undesired events, listed by body system, have been reported with the following frequencies: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) including isolated reports, not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:602px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Purpura, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Sleep disturbances of the type noted with other beta-blockers</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Mood changes, nightmares, confusion, psychoses and hallucinations</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Dizziness, headache, paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Dry eyes, visual disturbances</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Bradycardia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Heart failure deterioration, precipitation of heart block</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Cold extremities</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Postural hypotension which may be associated with syncope, intermittent claudication may be increased if already present, in susceptible patients Raynaud&#39;s phenomenon</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Bronchospasm may occur in patients with bronchial asthma or a history of asthmatic complaints</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Gastrointestinal disturbances</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Elevations of transaminase levels</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hepatic toxicity including intrahepatic cholestasis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Alopecia, psoriasiform skin reactions, exacerbation of psoriasis, skin rashes</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions, including angioedema and urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Lupus-like syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Impotence</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>An increase in ANA (Antinuclear Antibodies) has been observed, however the clinical relevance of this is not clear</p></td></tr></tbody></table><p>Discontinuance of the drug should be considered if, according to clinical judgement, the well-being of the patient is adversely affected by any of the above reactions.</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme website:&nbsp;<u>www.mhra.gov.uk/yellowcard</u>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.9 Overdose</strong></p><p>The symptoms of overdosage may include bradycardia, hypotension, acute cardiac insufficiency and bronchospasm.</p><p>General treatment should include: close supervision; treatment in an intensive care ward; the use of gastric lavage; activated charcoal and a laxative to prevent absorption of any drug still present in the gastrointestinal tract; the use of plasma or plasma substitutes to treat hypotension and shock. The possible uses of haemodialysis or haemoperfusion may be considered.</p><p>Excessive bradycardia can be countered with atropine 1&ndash;2 mg intravenously and/or a cardiac pacemaker. If necessary, this may be followed by a bolus dose of glucagon 10 mg intravenously. If required, this may be repeated or followed by an intravenous infusion of glucagon 1&ndash;10 mg/hour depending on response. If no response to glucagon occurs or if glucagon is unavailable, a beta-adrenoceptor stimulant such as dobutamine 2.5 to 10 micrograms/kg/minute by intravenous infusion may be given. Dobutamine, because of its positive inotropic effect could also be used to treat hypotension and acute cardiac insufficiency. It is likely that these doses would be inadequate to reverse the cardiac effects of beta-blocker blockade if a large overdose has been taken. The dose of dobutamine should therefore be increased if necessary to achieve the required response according to the clinical condition of the patient.</p><p>Bronchospasm can usually be reversed by bronchodilators.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 Pharmacodynamic properties</strong></p><p>Pharmacotherapeutic group: Beta-blocking agents, plain, selective, ATC code: CO7A B03<strong>.</strong></p><p><strong><u>Mechanism of action</u></strong></p><p>Atenolol is a beta-blocker which is beta<sub>1</sub>-selective, (i.e. acts preferentially on beta<sub>1</sub>-adrenergic receptors in the heart). Selectivity decreases with increasing dose.</p><p>Atenolol is without intrinsic sympathomimetic and membrane-stabilising activities and as with other beta-blockers, has negative inotropic effects (and is therefore contraindicated in uncontrolled heart failure).</p><p>As with other beta-blockers, the mode of action of atenolol in the treatment of hypertension is unclear.</p><p>It is probably the action of atenolol in reducing cardiac rate and contractility which makes it effective in eliminating or reducing the symptoms of patients with angina.</p><p>It is unlikely that any additional ancillary properties possessed by S (-) atenolol, in comparison with the racemic mixture, will give rise to different therapeutic effects.</p><p><strong><u>Clinical efficacy and safety</u></strong></p><p>Atormin is effective and well-tolerated in most ethnic populations although the response may be less in black patients.</p><p>Atormin is effective for at least 24 hours after a single oral dose. The drug facilitates compliance by its acceptability to patients and simplicity of dosing. The narrow dose range and early patient response ensure that the effect of the drug in individual patients is quickly demonstrated. Atormin is compatible with diuretics, other hypotensive agents and antianginals (see section 4.5). Since it acts preferentially on beta-receptors in the heart, Atormin may, with care, be used successfully in the treatment of patients with respiratory disease, who cannot tolerate non-selective beta-blockers.</p><p>Early intervention with Atormin in acute myocardial infarction reduces infarct size and decreases morbidity and mortality. Fewer patients with a threatened infarction progress to frank infarction; the incidence of ventricular arrhythmias is decreased and marked pain relief may result in reduced need of opiate analgesics. Early mortality is decreased. Atormin is an additional treatment to standard coronary care.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.2 Pharmacokinetic properties</strong></p><p><strong><u>Absorption</u></strong></p><p>Absorption of atenolol following oral dosing is consistent but incomplete (approximately 40&ndash;50%) with peak plasma concentrations occurring 2&ndash;4 hours after dosing. The atenolol blood levels are consistent and subject to little variability. There is no significant hepatic metabolism of atenolol and more than 90% of that absorbed reaches the systemic circulation unaltered.</p><p><strong><u>Distribution</u></strong></p><p>Atenolol penetrates tissues poorly due to its low lipid solubility and its concentration in brain tissue is low. Plasma protein binding is low (approximately 3%).</p><p><strong><u>Elimination</u></strong></p><p>The plasma half-life is about 6 hours but this may rise in severe renal impairment since the kidney is the major route of elimination.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.3 Preclinical safety data</strong></p><p>Atenolol is a drug on which extensive clinical experience has been obtained. Relevant information for the prescriber is provided elsewhere in the Prescribing Information.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6. Pharmaceutical particulars</strong></p><p><strong>6.1 List of excipients</strong></p><p>Microcrystalline Cellulose (Avicel PH 102)</p><p>Sodium Lauryl Sulphate</p><p>Sodium Starch Glycolate</p><p>Colloidal Anhydrous Silica</p><p>Magnesium Stearate</p><p>Tabcoat TC White</p><p>Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.2 Incompatibilities</strong></p><p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                6.3 Shelf life
36 months.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.4 Special precautions for storage</strong></p><p>Store between 15˚C to 25˚C</p><p>Protect from light and moisture. Keep out of the reach of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.5 Nature and contents of container</strong></p><p>Aluminium / PVC Blister pack: 28&rsquo;s (14&rsquo;s blister x 2) &amp; 700 (14&rsquo;s Blister x 50)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.6 Special precautions for disposal and other handling</strong></p><p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7. Marketing authorisation holder
Oman Pharmaceutical products Co., LLC,
Salalah, Oman

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January2014 and July 2009 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>